Nam Jong Kil, Lee Dong Hoon, Park Sung Woo, Kam Sung Chul, Lee Ki Soo, Kim Tae Hyo, Kim Taek Sang, Oh Cheol Kyu, Park Hyun Jun, Kim Tae Nam
Department of Urology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Department of Urology, Gyeongsang National University Hospital, Jinju, Korea.
World J Mens Health. 2017 Apr;35(1):28-33. doi: 10.5534/wjmh.2017.35.1.28.
The aim of this study was to assess the clinicopathologic characteristics of penile cancer, including patterns of therapy, oncologic results, and survival.
Between January 2005 and July 2015, 71 patients at 6 institutions who had undergone penectomy or penile biopsy were enrolled. Their medical records were reviewed to identify the mode of therapy, pathology reports, and cancer-specific survival (CSS) rate.
Clinicopathologic and outcome information was available for 52 male patients (mean age, 64.3 years; mean follow-up, 61.4 months). At presentation, 17 patients were node-positive, and 4 had metastatic disease. Management was partial penectomy in 34 patients, total penectomy in 12 patients, and chemotherapy or radiotherapy in 6 patients. The pathology reports were squamous cell carcinoma in 50 patients and other types of carcinoma in the remaining 2 patients. Kaplan-Meier survival analysis showed a 5-year CSS rate of 84.0%. In univariate and multivariate analyses, the American Joint Committee on Cancer (AJCC) stage and pathologic grade were associated with survival.
Partial penectomy was the most common treatment of penile lesions. The oncologic outcomes were good, with a 5-year CSS of 84.0%. The AJCC stage and pathologic grade were independent prognostic factors for survival.
本研究旨在评估阴茎癌的临床病理特征,包括治疗方式、肿瘤学结果和生存率。
2005年1月至2015年7月期间,纳入了6家机构中71例接受阴茎切除术或阴茎活检的患者。回顾他们的病历以确定治疗方式、病理报告和癌症特异性生存率(CSS)。
52例男性患者(平均年龄64.3岁;平均随访61.4个月)有临床病理和结局信息。就诊时,17例患者淋巴结阳性,4例有转移性疾病。34例患者行部分阴茎切除术,12例患者行全阴茎切除术,6例患者行化疗或放疗。病理报告显示50例为鳞状细胞癌,其余2例为其他类型的癌。Kaplan-Meier生存分析显示5年CSS率为84.0%。单因素和多因素分析显示,美国癌症联合委员会(AJCC)分期和病理分级与生存率相关。
部分阴茎切除术是阴茎病变最常见的治疗方法。肿瘤学结果良好,5年CSS为84.0%。AJCC分期和病理分级是生存的独立预后因素。